SCHEMBL5043426

SCHEMBL5043426

CCOC(=O)c1ccc(C#Cc2ccc3c(c2)OCC(C)(C)CO3)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
CYP3A4 P08684 2/20 0.60
RARA P10276 1/20 0.60
RARB P10826 1/20 0.60
RARG P13631 1/20 0.60
ACACB O00763 1/20 0.46
CYP26A1 O43174 1/20 0.43
OGA O60502 2/20 0.42
MAPT P10636 6/20 0.41
RAB9A P51151 4/20 0.41
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
USP2 O75604 2/20 0.41
TSHR P16473 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 1/20 0.41
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046536 0.88 ACACB (0.54) KMT2ACYP3A4RARARARBRARG
SCHEMBL8460127 0.85 KMT2A (0.62) KMT2ACYP3A4RARARARBRARG
SCHEMBL5048039 0.83 ACACB (0.48) KMT2ACYP3A4RARARARBRARG
SCHEMBL5046831 0.83 ACACB (0.49) KMT2ACYP3A4RARARARBRARG
SCHEMBL1485972 0.81 RARA (0.70) KMT2ACYP3A4RARARARBRARG
SCHEMBL5046606 0.80 MAPT (0.56) KMT2AMAPTRAB9ALMNAMEN1
SCHEMBL8626930 0.79 CYP3A4 (0.65) KMT2ACYP3A4RARARARBRARG
SCHEMBL9334969 0.79 RARA (0.62) KMT2ACYP3A4RARARARBRARG
SCHEMBL9270697 0.79 CYP3A4 (0.77) KMT2ACYP3A4RARARARBRARG
SCHEMBL9024941 0.79 RARB (0.64) KMT2ACYP3A4RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP claimed
EP-1682528-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP claimed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US claimed
WO-2005044814-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-19 WO claimed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
EP-1682528-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed
WO-2005044814-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 KMT2A 3273/4885CYP3A4 84/4885RARA 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.